Duodenal mucosal resurfacing prevents weight regain after stopping GLP-1 drugs

9 articles · Updated · SciTechDaily · Apr 28

A blinded, randomized trial led by Dr. Shelby Sullivan found patients regained only 7 pounds six months after stopping tirzepatide, while controls regained about twice as much.
The minimally invasive procedure, tested in 45 participants, showed durable benefits, with the treatment group maintaining over 80% of their original weight loss and no serious complications reported.
Duodenal mucosal resurfacing targets the gut lining to reset metabolism, addressing a major unmet need for post-GLP-1 therapy weight maintenance. Larger trial results are expected later in 2026.

With borderline pilot data, can the pivotal trial prove DMR is a definitive weight-loss solution?

Will the cost of Revita make it a viable 'off-ramp' from expensive GLP-1 medications?

Could this procedure eventually replace daily medications for type 2 diabetes management?

What are the unknown long-term risks of permanently altering the small intestine with this procedure?

Does the metabolic 'reset' from DMR last for years, or will patients need repeat treatments?

How will this heat-based therapy compare to emerging non-thermal procedures targeting the same organ?